Hims & Hers Expands Globally with ZAVA Acquisition and New Semaglutide Offerings

Hims & Hers will offer generic semaglutide in Canada after Novo Nordisk's patent on Ozempic and Wegovy expired in January 2023 due to non-payment of maintenance fees, opening the market for more affordable weight loss treatments. The Canadian market for semaglutide is rapidly growing, and Hims aims to provide accessible, high-quality care, although the approval process for generics is still underway. Novo Nordisk's patent lapse was due to administrative oversight, and the company has stated that patent expirations are part of the normal lifecycle of pharmaceutical products.